Scienture Holdings, Inc. - Common Stock SCNX 深 滬
等待開盤 09-10 09:30:00 美东时间
0.857
-0.032
-3.61%
華盛通- 最 高0.8825
- 今 開0.863
- 成交量 11.39万股
- 最 低 0.8334
- 昨 收 0.8891
- 總市值 1124.08万
- 52周最高 9.55
- 市盈率 靜 --
- 換手率 0.87%
- 52周最低 0.69
- 委 比 -50.00%
- 總股本 1311.64万
- 歷史最高 164.50
- 量 比 0.51
- 振 幅 5.52%
- 歷史最低 -5.81
- 每 手 1
- 風險率 2.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
Scienture Holdings, Inc. (NASDAQ: SCNX) has entered into a securities purchase agreement with institutional investors for a registered direct offering of 3,225,000 common shares at $1.20 per share, raising approximately $3.9 million. The offering is expected to close on August 15, 2025, subject to customary conditions. Maxim Group LLC is acting as the sole placement agent. The offering is made under a shelf registration statement on Form S-3 (Fil...
08-14 13:00
Scienture Launches Arbli, First FDA-Approved Ready-To-Use Liquid Losartan
SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing,
08-13 20:17
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
SCIENTURE HOLDINGS, INC. announced the shipment of Arbli<sup>™</sup> (losartan potassium) Oral Suspension, 10 mg/mL, a first-of-its-kind FDA-approved ready-to-use liquid losartan formulation for treating hypertension, reducing stroke risk, and managing diabetic nephropathy.arbli<sup>™</sup> eliminates the need for compounding and offers a convenient, safe option for patients. The company has received its first order, marking a major milestone tow...
08-13 12:05
Scienture Holdings Q2 EPS $(0.48) Up From $(1.16) YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.48) per share. This is a 58.62 percent increase over losses of $(1.16) per share from the same period last year.
08-12 21:32
Scienture files $200M mixed securities shelf
Scienture Holdings (NASDAQ:SCNX) filed $200M mixed securities shelf. This preliminary prospectus is not an offer to sell. Filing More on Scienture Holdings, Inc. Scienture appoints Hariharan, Mani as ...
08-02 05:29
Scienture Holdings Secures $1.2 Million in Capital Raise
Scienture Holdings ( ($SCNX) ) has issued an announcement. On July 24, 2025, Sc...
07-25 05:49
Scienture secures $1.2 million in bridge funding
Scienture (NASDAQ:SCNX) has approved a bridge funding raise of up to an aggregate amount of $3M, of which it has secured about $1.2M, through the issuance of shares of the company’s common stock to in...
07-25 05:27
Scienture Holdings' Boards Of Directors Approve A Bridge Funding Raise Of Up To An Aggregate Amount Of $3M, Of Which It Has Secured ~ $1.2M
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value
07-25 05:15
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
Sciencure Holdings Inc. (NASDAQ: SCNX) announced that its board of directors approved a bridge funding raise of up to $3 million, with $1.2 million secured through issuing common stock to institutional or accredited investors. The funding does not include warrants, options, or other convertible securities, reflecting strong investor support. The funds will be used to support upcoming product launches and pipeline development. Executives expressed...
07-24 21:12
